Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.
포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.
터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
MaxCyte, Inc. 31 January 2025 MaxCyte, Inc. ("MaxCyte" or the "Company") Exercise of options and PDMR dealing ROCKVILLE, MD, January 31...
MaxCyte Inc on Thursday said it has acquired SeQure Dx Inc, as it looks to improve its gene therapy testing process. ...
MaxCyte, Inc. 30 January 2025 MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing...
ROCKVILLE, Md., Jan. 30, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading...
MaxCyte, Inc. 29 January 2025 TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the...
MaxCyte, Inc. 22 January 2025 TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the...
MaxCyte, Inc. 21 January 2025 TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the...
MaxCyte, Inc. 17 January 2025 TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the...
MaxCyte, Inc. 15 January 2025 TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the...
MaxCyte Inc on Monday raised its 2024 revenue guidance above initial expectations, and above the updated guide report ...
MaxCyte, Inc. 13 January 2025 MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results ROCKVILLE, MD...
ROCKVILLE, Md., Jan. 13, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading...
MaxCyte, Inc. 02 January 2025 MaxCyte, Inc. ("MaxCyte" or the "Company") Total Voting Rights ROCKVILLE, MD, January 2, 2025: MaxCyte...
MaxCyte, Inc. 31 December 2024 MaxCyte, Inc. ("MaxCyte" or the "Company") Exercise of options and PDMR dealing ROCKVILLE, MD, December...
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관
광고 없는 경험을 위해 가입하세요
지금 사용해 보세요
광고 유지